QNRX: כמות מזומנים למניה Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals' focus on patents within the orphan dermatology niche drives its financial dynamics. Cash per share visualizes current capital, where 6.90 reflects the latest value of the metric. Diversified European and US manufacturing outsourcing reduces logistical risks, although high development costs and dependence on clinical outcomes create certain pressure on balance sheet liquidity.
פילוחים אנליטיים של חברת Quoin Pharmaceuticals

Cash per share determines the level of direct liquidity available to each security holder. Daily recalculations eliminate accounting lags, capturing real-time changes in the volume of free cash. By analyzing the cash per share figure, an investor assesses protection against liquidity gaps. Growth in this metric is critically important for Quoin Pharmaceuticals (QNRX), as it ensures the funding for the development of drugs to treat rare skin pathologies.